This Week in Practical Diabetology News

Week of November 26, 2018

Healio: Diabetic Retinopathy Linked to Glycemic Variability in Type 2 Diabetes

“The aim of the recent study, published in the Journal of Diabetes Investigation, was to evaluate the link between several short-term [glycemic variability] measurements, as assessed by CGM, and the prevalence of [diabetic retinopathy] in patients with LADA and type 2 diabetes mellitus.” Learn more about the study.

MD Linx: Diabetic Ketoacidosis Further Increases Risk of Alzheimer’s Disease in Patients with Type 2 Diabetes

“Using Taiwan’s National Health Insurance database, researchers conducted a retrospective nationwide population-based cohort study to determine whether diabetic ketoacidosis (DKA) further increases the risk of dementia in patients with Type 2 diabetes mellitus (DM), a known risk factor for dementia.” Learn about the findings.

Pharmacy Times: Shoe Insole May be a Help for Patients with Diabetic Foot Ulcers

Recently, Purdue researchers developed a shoe insole that could help make the healing process more portable for the 15 percent of Americans who develop diabetic foot ulcers. Learn more about the innovation.

Medscape: Can Diet Reverse Type 2 Diabetes?

“Recent studies have suggested that T2D can actually be reversed, not through novel pharmaceutical treatments but through strict adherence to certain dietary interventions.” Learn about recent studies supporting this statement.

Healio: FDA Suspends Clinical Trial for Investigational Diabetes Drug

“The FDA placed a clinical hold on an investigational new drug application for a second-generation MetAP2 inhibitor in development for the treatment of Type 2 diabetes, citing cardiovascular safety concerns, Zafgen announced in a press release.” Learn more about the FDA decision.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of November 8, 2018

MedPage Today: Colectomy May Boost Diabetes Risk

“Patients who undergo colectomy — particularly resection of the left colon — appear to have an increased risk of developing type 2 diabetes, according to Danish researchers.” Learn more about the study published in eLIFE.

Medscape: Diabetes Advocates: House Insulin Cost Report Lacks Bite

“Advocates of individuals with diabetes say they welcome a new US House-issued report on the high cost of insulin, but some believe that although it is a significant step, the report fails in not calling for immediate action.” Learn more about the report issued by US Representatives Diana DeGette (D-CO) and Tom Reed (R-NY), cochairs of the Congressional Diabetes Caucus.

Medscape: Gestational Diabetes Up Slightly in United States

“The prevalence of gestational diabetes in the United States has risen slightly since 2012, whereas that of women with diabetes before pregnancy has remained stable, according to new data from the National Center for Health Statistics.” Read more in Medscape.

HealthDay: Could Diabetes Drugs Help Curb Alzheimer’s?

“Alzheimer’s patients taking diabetes drugs may have fewer signs of dementia in their brains than similar patients not taking the drugs, new research finds. Specifically, the post-mortem study found that people who’d taken diabetes meds had fewer abnormalities in tiny blood vessels in their brains, and less abnormal gene activity.” Read the full story.

Making System-wide Improvements in Diabetes Care

How do you make changes that will have a system-wide impact on care for patients with diabetes? Read 6 tips from John W. Kennedy, MD, chief medical officer, AMGA, and president, AMGA Foundation. Read the full NIDDK article.

Medical Xpress: Improved Rescue Kits for People With Diabetes, Hypoglycemia

Purdue University researchers are working on a solution similar to common EpiPen devices that could help diabetic patients and others with hypoglycemia. Learn more about the innovative technology.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of October 1, 2018

Medical News Today: Type 2 diabetes: Five genetic ‘clusters’ may explain evolution

Research teams at Massachusetts Institute of Technology, Harvard University and other area institutions have identified five clusters of genetic variants that may influence distinct subtypes of Type 2 diabetes. Learn more about the findings, published in the journal PLOS Medicine.

Healio: Diabetes vaccine may follow from celiac disease research

As Healio reports, the JDRF T1D Fund is investing in ImmusanT, a clinical-stage company looking to develop a vaccine to prevent Type 1 diabetes following on its peptide immunotherapy program for celiac disease, the two entities announced in a press release. Read the full story.

Diabetes.co.uk: New approach could better predict coronary artery disease in people with Type 2 diabetes

In a recent study, Joslin Diabetes Center scientists found adding genetics to future analyses could help further predict someone’s coronary artery disease (CAD) risk in people with Type 2 diabetes. Learn more about the study published in Diabetes Care.

The New Indian Express: Vitamin B may boost kidney function in young diabetics

According to a recent study, adolescents managing Type 1 diabetes may benefit from Vitamin B supplements. Learn more about the study, presented at the 57th Annual European Society for Paediatric Endocrinology Meeting.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Endocrinology Advisor: Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes

According to a recent study published in the Journal of the American College of Cardiology, intensive blood pressure (BP) therapy may significantly lower the risk for serious cardiovascular events in the adult population with diabetes in the United States. Learn more about the study in Endocrinology Advisor.

Medscape: Psoriasis/Psoriatic Arthritis Tied to Increased Diabetes Risk

According to a large cohort study published online September 12 in Rheumatology, patients with psoriatic arthritis (PsA) and psoriasis may have an increased risk for Type 2 diabetes (T2D). In addition to PsA and psoriasis, researchers found an increase in risk of the combined cardiovascular diseases, [ischemic heart disease,] and [peripheral vascular disease].  Read more about the study.

Healio: Early Engagement, Intervention ‘Crucial’ for Children Diagnosed With Type 2 Diabetes

Children newly diagnosed with Type 2 diabetes are at high risk for disease-related complications, including a fourfold increase in microalbuminuria over 1 year. However, according to findings published in Pediatric Diabetes, weight loss and taking medications as prescribed can improve long-term outcomes. Learn more about the study and why, “weight loss and treatment adherence are the key to better outcomes a year from diagnosis for Type 2 diabetes.”

Medscape: Urologic Complications Common in Type 1 Diabetes

Is there a connection between Type 1 diabetes and urologic complications? A new study says yes. The research findings, derived from an ancillary study to the Epidemiology of Diabetes Interventions and Complications (EDIC) study — the observational follow-up to the landmark Diabetes Control and Complications Trial (DCCT) — found about two thirds of adults with long-duration Type 1 diabetes experience urologic complications. Learn more about the study published online August 13 in Diabetes Care.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of September 10, 2018

The Herald Dispatch: Medical Device Network: MU scientist awarded grants for obesity, diabetes research

Jung Han Kim, Ph.D., a professor in the departments of biomedical research and clinical and translational science at the Marshall University Joan C. Edwards School of Medicine received a $440,405, three-year grant from the National Institutes of Health (NIH) to study genes causing diabetes by analyzing the interaction between genes and diet. Kim is also the recipient of a $154,000 two-year grant from the American Heart Association for a study that tests links between genetic variants and obesity susceptibility. Read more about the NIH grant.

General Electric and DARPA partner for diabetes research project

General Electric (GE) and the Defense Advanced Research Projects Agency (DARPA) are collaborating on a $2.9m research project to develop non-drug treatments for diabetes. Learn more about the three-year research project.

Healio: California’s Medi-Cal makes strides in diabetes epidemic

Medi-Cal managed care plans in California are making progress in the state’s costly and deadly diabetes epidemic, according to a report commissioned by the California Optometric Association.

Through the newly developed “Diabetes Days” program, community health centers for diabetic patients, are partnering with the Anthem Blue Cross Medi-Cal plan and connecting members with life-saving, comprehensive diabetes screenings including eye exams. Read more about the program.

Annals of Internal Medicine: Clinical Guidelines

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus. Read the abstract.

Healio: WHO releases recommendations for treating adults with diabetes

WHO released recommendations regarding which medicines should be used for treatment intensification in adult patients with type 2 diabetes as well as the use of analogue or human insulin in Type 1 and 2 diabetes. Get the details.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Healthline: Researchers Find Evidence Keto Diet May Increase Type 2 Diabetes Risk

The ketogenic diet’s popularity has resurged as a strategy to lose weight quickly. The diet is very high fat and extremely low in carbohydrates with the purpose of putting the body into ketosis to use fat as fuel. But a recent study, published in The Journal of Physiology, says following the diet in its early phases could boost the risk for Type 2 diabetes. Read the full story.

Science Daily: New medical specialty needed to manage growing number of Americans with diabetes

Fourteen years after one-year fellowship programs were created to give primary care physicians the clinical skills to better manage diabetes and its complications, new research, provided by the American Osteopathic Association, finds resistance among payers and other physicians may slow growth of the fledgling specialty. Read the full story.

Healio Endocrine Today: In new era of diabetes tech, advancements poised to change management for Type 1 and Type 2

Nearly 70 percent of Americans own a smartphone, and for individuals with diabetes, these devices — specifically phone apps — have become an integral part of their everyday lives because they house tools to help stay on a healthy diabetic track. What are the new technology trends for diabetes management? Endocrine Today shares their insights. Get the technology updates.

Science Daily: Consuming milk at breakfast lowers blood glucose throughout the day

As reported by Science Daily,  change in breakfast routine may provide benefits for the management of Type 2 diabetes, according to a new study. Learn more about the potential health benefits.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of August 20, 2018

Similar A1c Effect for Intermittent vs Continually Restricted Diets

Researchers found that intermittent semi-fasting, with daily caloric intake kept below 600 kcal for 2 days per week, yielded a similar reduction in blood glucose when compared with a continual calorie-restricted diet. MedPage Today outlined these research findings. Click here for full story.

Nonheterosexual Youth May Be at Greater Diabetes Risk

Nonheterosexual adolescents may be at greater risk for developing type 2 diabetes compared with heterosexual teens, new research suggests. The study, reviewed by Medscape, was based on national data for 350,673 high school students aged 14–18 years who participated in the Youth Risk Behavior Survey (YRBS) during 2009–2015. Click here for full story.

Preventing dangerous episodes of low blood sugar with diabetes: Study provides next clue

A new study reveals that a novel biomarker might give us new answers necessary to creating a diagnostic tool for hypoglycemia-associated autonomic failure, or HAAF. Science Daily reports, no objective diagnostic tool currently exists for this condition which, if left untreated, can lead to ever-worsening and possibly life-threatening episodes of dangerously low blood sugar. Click here for full story.

Masked High Blood Pressure and Arterial Stiffness in Type 1 Diabetes

A recent ambulatory blood pressure (BP) monitoring analysis indicated that many individuals with type 1 diabetes also have masked hypertension, according to a study highlighted by Endocrinology Advisor. Research also suggested increased arterial stiffness and a greater risk for cardiovascular disease in these individuals. Click here for full story.

Diabetes drugs act as powerful curb for immune cells in controlling inflammation

According to a report on Science Daily, a common class of drugs used to treat diabetes has been found to exert a powerful check on macrophages by controlling the metabolic fuel they use to generate energy. Keeping macrophages from going overboard on the job may inhibit the onset of obesity and diabetes following tissue inflammation. Click here for full story.

Novel Therapies for Diabetes Mellitus in Pregnancy

The prevalence of diabetes during pregnancy has been increasing in recent years, according to a report on Practice Update. it is now more important than ever to understand the best treatment strategies for minimizing risk to both the mother and the unborn child. Click here for full story.

Poor Periconception Glycemic Control in Women With Type 1 Diabetes Increases Risk of Major Birth Defects

As stated by Practice Update, the authors of this population-based historical cohort study of 2458 singleton live-born infants of mothers with type 1 diabetes and 1,159,865 infants of mothers without diabetes sought to determine the association between maternal type 1 diabetes and the risk of major birth defects according to levels of HbA1c within 3 months before or after estimated conception. Click here for full story.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of July 16, 2018

Newer Diabetes Agents Show Promise for Renal Disease

Healio reports that large cardiovascular outcome trials for antidiabetes agents in two drug classes have yielded potentially promising data with respect to their secondary renal outcomes, offering new options for patients with diabetic kidney disease. Click here for full story.

Consider Patient Risk When Targeting BP in Diabetes

A debate continues over the optimal target for blood pressure management in type 2 diabetes with comorbid hypertension. Healio reports that some experts are pushing for a lower goal whenever possible, whereas others prefer a more individualized, patient-centered approach. Click here for full story.

TEDDY: More Small Clues to the Pathogenesis of Type 1 Diabetes

Medscape reports that more small clues to the development of islet autoimmunity prior to the onset of type 1 diabetes are emerging from The Environmental Determinants of Diabetes in the Young study. Click here for full story.

HbA1c Reduction Similar in Old, New Basal Insulin Analogues

Despite some differences in weight gain, most basal insulin analogs generally have similar glycemic control efficacy for patients with type 2 diabetes, according to a new study outlined by MedPage Today. Click here for full story.

‘Really Good’ New Guidelines for T2 Diabetes

Dr. Anne Peters talks about the new ASA/EASD treatment guidelines for managing patients with Type 2 diabetes for Medscape. Although guiding people is difficult, these guidelines actually begin to guide us in the treatment of our patients with type 2 diabetes. Click here for full story.

Experts Weigh Pros, Cons of Second-Line Diabetes Therapies

As reported by Healio, panelists at the Heart in Diabetes Clinical Education Conference presented their respective arguments for their choice of SGLT2 inhibitors vs. GLP-1 receptor agonists as second-line therapy after metformin. Click here for full story.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of July 9, 2018

Scientists Discover New Target to Treat Blood Vessel Damage in Diabetes

For those with diabetes, both the tightly woven endothelial cells that line our blood vessels and the powerhouses that drive those cells start to come apart as early steps in the destruction of our vasculature. As reported by News Medical, scientists now have evidence that these breakups occur as another relationship falls apart. Click here for full story.

Increased Incidence of Hospitalization for Heart Failure in People With Diabetes

According to a report from Practice Update, a study has found that heart failure is an under-recognized complication of Type 1 diabetes. The study found that people with diabetes had an increased incidence of hospitalization for heart failure. Click here for full story.

Verapamil May Improve Beta-Cell Function in Type 1 Diabetes

New research suggests that the old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with Type 1 diabetes. As reported by Medscape, verapamil appears to bolster the remaining endogenous beta-cell function, which has been shown to persist in people with type 1 diabetes longer than previously thought. Click here for full story.

Oestrogen Holds Promise for Diabetes Cure

Oestrogen can protect women who have been through menopause against Type 2 diabetes, according to a report outlined by Nature. Oestrogen does so by triggering the destruction of misfolded insulin proteins that accumulate during the early stages of the disease. Click here for full story.

Researchers Cure Type 2 Diabetes and Obesity in Mice Using Gene Therapy

A research team from the Universitat Autònoma de Barcelona, led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy. As reported by MedicalXpress the gene therapy promoted healthy aging and prevented age-associated weight gain and insulin resistance in mice. Click here for full story.

Intensifying Treatment Does Not Negatively Affect Type 2 Diabetes

A new study outlined by Endocrinology Advisor found that intensifying treatment, including initiation of insulin, does not have an adverse impact on the well-being of community-dwelling patients with Type 2 diabetes. Previous research shows that the initiation of insulin did not affect health status or quality of life (QoL), although patients on chronic insulin therapy have demonstrated lower health status and diabetes-associated QoL vs those on other therapies. Click here for full story.

Very High HbA1c Falls Most With GLP-1 Agonist Plus Basal Insulin

Among patients with uncontrolled type 2 diabetes with very high HbA1c, two treatment regimens led to “dramatic improvements” in glycemic control at 6 months, but one strategy stood out, Medscape reports. A treatment regimen of basal insulin plus the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (Victoza, Novo Nordisk) was more effective at lowering HbA1c than a regimen of basal plus bolus insulin. Click here for full story.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.


Week of July 2, 2018

Carol and Mark A. Atkinson, PhD, Receive American Diabetes Association’s Humanitarian Award

Last week at the ADA’s 78th Scientific Sessions, Carol and Mark A. Atkinson, PhD, of Insulin for Life USA, received the American Diabetes Association’s Humanitarian Award. This one-time award honors their outstanding leadership and humanitarian efforts to support the diabetes community for the Diabetes Emergency Relief Coalition in 2017. Both Carol and Mark A. Atkinson will have upcoming contributions to the Practical Diabetology editorial line-up. Click here for full story.

RISE: Type 2 Diabetes More Aggressive in Adolescents; Early Treatment Unlikely to Slow Progression

According to new data from three RISE Studies, and outlined by Healio, early treatment with insulin and metformin does not substantially slow the progression of prediabetes or newly diagnosed Type 2 diabetes in adolescents, and they have a much more aggressive disease than adults with similar glycemic profiles. Click here for full story.

There’s Hope For a Vaccine to Prevent Type 1 Diabetes

In a new study, a small group of people with type 1 diabetes who were given a vaccine showed improvement in their blood sugar levels to nearly normal levels—and the changes lasted for five to eight years. As reported by Time Health, levels of their HbA1c dropped more than 10% three years after treatment and by more than 18% four years after treatment. Click here for full story.

FDA Clears New Point-of-Care HbA1c Assay

As reported by Healio, the FDA has cleared a rapid point-of-care test to diagnose diabetes and assess patient risk for developing diabetes. The Afinion HbA1c Dx assay is now cleared for use with the Afinion AS100 Analyzer, a multi-assay analyzer that provides near-patient testing of HbA1c and albumin to creatinine ratio at the point of care, according to a press release from Abbott. Click here for full story.

Novel Systems Could Expand ‘Hybrid Closed-Loop’ Field in Diabetes

Findings for three insulin delivery systems show promise for improving blood glucose levels in people with Type 1 diabetes. As reported by Medscape, the new data were discussed during a press briefing moderated by Irl B. Hirsch, MD, of the University of Washington, Seattle at the American Diabetes Association 2018 Scientific Sessions. Click here for full story.

Cost Issues Prevent a Quarter of Patients From Taking Insulin

A new study shows Cost issues related to insulin use prevent a full quarter of patients with diabetes taking insulin as prescribed. The study outlined by Medscape states that these cost issues are associated with poorer glycemic control. Click here for full story.

For more research updates and clinician-focused insights, bookmark PracticalDiabetology.com.

Pages: 1 2

Learn more about the health and medical experts who who provide you with the cutting-edge resources, tools, news, and more on Practical Diabetology.
About Our Experts >>